Catalog No.
Product Name
Application
Product Information
Citations
-
AKT Inhibitor
AKT-IN-23 is a selective inhibitor of the AKT kinase, a crucial component in the PI3K/AKT signaling pathway. This compound effectively inhibits AKT activity, leading to decreased cell proliferation and survival in various cancer cell models. AKT-IN-23 is useful in cancer research, particularly in studies focused on the modulation of signaling pathways associated with tumor progression and therapeutic resistance. -
Akt Inhibitor
Hu7691 free base is a selective inhibitor of AKT, demonstrating IC50 values of 4.0 nM, 97.5 nM, and 28 nM for AKT1, AKT2, and AKT3, respectively. This compound exhibits significant antitumor activity and has been shown to reduce cutaneous toxicity in murine models. Hu7691 free base is valuable in research focused on cancer therapeutics and the modulation of the AKT signaling pathway. -
PROTAC AKT Degrader
MS98 is a selective PROTAC degrader targeting AKT, effectively inducing the degradation of total AKT (T-AKT) with a DC50 value of 78 nM. This compound demonstrates high-affinity binding to AKT isoforms, with Kd values of 4 nM, 140 nM, and 8.1 nM for AKT1, AKT2, and AKT3, respectively. MS98 is valuable for research applications in understanding AKT signaling pathways and developing therapeutic strategies for cancer and other diseases associated with dysregulated AKT activity. -
AKT Inhibitor
AT7867 hydrochloride is a potent inhibitor of AKT and p70 S6 kinase, exhibiting strong oral activity. This compound demonstrates significant anticancer properties, making it a valuable tool in cancer research. Its efficacy in targeting critical signaling pathways involved in cellular growth and survival supports its use in exploring therapeutic strategies for various malignancies. -
Allosteric Akt Inhibitor
MK-2206 free base is a highly potent and selective allosteric inhibitor of the Akt signaling pathway, exhibiting IC50 values of 8 nM, 12 nM, and 65 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anticancer properties, particularly against breast cancer cell lines, as well as those harboring PIK3CA mutations and PTEN loss. MK-2206 free base is valuable for research applications focused on cancer biology and therapeutic development targeting the Akt pathway. -
Akt1/Akt2 Inhibitor
AKT-IN-5 is a selective inhibitor of Akt1 and Akt2, exhibiting IC50 values of 450 nM and 400 nM, respectively. This compound has been shown to effectively modulate the Akt signaling pathway, which plays a critical role in cell survival, proliferation, and metabolism. AKT-IN-5 is valuable for research applications focused on cancer biology, metabolic disorders, and other conditions driven by aberrant Akt activity. -
PI3Kδ Inhibitor
PI3Kδ-IN-10 is a potent and orally bioavailable inhibitor of the PI3Kδ enzyme, exhibiting an IC50 value of 2 nM. This compound effectively inhibits the downstream AKT signaling pathway, leading to the induction of apoptosis in hepatocellular carcinoma models. Due to its mechanism of action, PI3Kδ-IN-10 is valuable for investigating the role of PI3Kδ in cancer biology and therapeutic development. -
AKT/mTOR/p70S6K Inhibitor
22-(4′-py)-JA is a semisynthetic derivative of junamycin A, primarily targeting the AKT/mTOR/p70S6K signaling pathway. This compound exhibits significant antimetastatic activity by inhibiting tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC). Furthermore, 22-(4′-py)-JA downregulates key factors including metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF). Its potent anticancer properties make it a valuable tool for research, particularly in non-small cell lung cancer (NSCLC) studies. -
PI3K/Akt/FoxO3a Inhibitor
RLX (PD 139530) is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, exhibiting significant therapeutic potential in colon cancer models. This compound can effectively modulate the tumor microenvironment, thereby enhancing the efficacy of cancer immunotherapy. Additionally, RLX improves the retention time of therapeutic agents in tumors through advanced nanoparticle delivery systems and can be combined with various treatment modalities, such as chemotherapy and radiotherapy, to synergistically enhance cancer treatment outcomes. -
Dual PI3K/mTOR Inhibitor
DHW-221 is a potent dual inhibitor of PI3K and mTOR, demonstrating low nanomolar potency across all four Class I PI3K isoforms (PI3Kα, IC50 = 0.50 nM; PI3Kβ, IC50 = 1.9 nM; PI3Kγ, IC50 = 1.8 nM; PI3Kδ, IC50 = 0.74 nM) and mTOR (IC50 = 3.9 nM). This compound exhibits significant antitumor activity by disrupting the PI3K/Akt/mTOR signaling pathway, promoting mitochondrial apoptosis and paraptosis via endoplasmic reticulum stress and MAPK signaling, while also hindering cell cycle progression, migration, invasion, and angiogenesis. DHW-221 serves as a valuable tool in research related to non-small cell lung cancer (NSCLC), colon cancer, and breast cancer. -
PI3K Inhibitor
Zandelisib hydrochloride is a selective, non-covalent inhibitor of PI3Kδ, known for its oral bioavailability. By effectively inhibiting AKT phosphorylation, Zandelisib hydrochloride disrupts downstream signaling pathways, making it a valuable tool for investigating the role of the PI3K pathway in various malignancies. This compound is particularly relevant in research focused on relapsed and refractory B-cell lymphoma, enabling studies on tumor behavior and therapeutic responses. -
AKT Inhibitor
AKT-IN-14 is a highly potent inhibitor of AKT, demonstrating IC50 values of less than 0.01 nM for AKT1, 1.06 nM for AKT2, and 0.66 nM for AKT3. This compound is primarily utilized in cancer research, providing valuable insights into AKT signaling pathways and therapeutic interventions. Its exceptional specificity and efficacy make it a crucial tool for investigating the role of AKT in tumorigenesis and cancer progression. -
PI3K/AKT Inhibitor
PI3K/AKT-IN-5 is a selective inhibitor of the PI3K/AKT signaling pathway. It demonstrates potent anti-cancer activity, particularly in colorectal cancer models, by significantly inhibiting cell colony formation, inducing G2/M phase cell cycle arrest, and promoting apoptosis. This compound serves as a valuable tool for research into the mechanisms of colorectal cancer progression and treatment. -
PI3Kδ Inhibitor
PI3Kδ-IN-11 is a potent and selective inhibitor of the PI3Kδ isoform, exhibiting an IC50 value of 27.5 nM. This compound effectively blocks the PI3K/Akt signaling pathway in a dose-dependent manner. PI3Kδ-IN-11 is particularly useful for studying B and T cell-related malignancies, providing valuable insights into therapeutic strategies targeting this pathway. -
AKT1 Inhibitor
AKT1-IN-10 is a non-covalent allosteric inhibitor of AKT1, exhibiting an IC50 of less than 500 μM. This compound demonstrates oral bioavailability, making it a viable candidate for in vivo studies. AKT1-IN-10 is primarily utilized in cancer research, providing insights into the modulation of AKT signaling pathways and their implications in tumor progression. -
AKT Inhibitor
AKT-IN-8 is a potent inhibitor of AKT, exhibiting IC50 values of 4.46 nM for AKT1, 2.44 nM for AKT2, and 9.47 nM for AKT3. This compound demonstrates significant inhibitory activity, making it a valuable tool for studying AKT signaling pathways. It is applicable in cancer research and investigations into the role of AKT in various cellular processes, including metabolism, proliferation, and survival. -
PROTAC Akt3 Degrader
PROTAC Akt3 Degrader-1 is a selective PROTAC degrader that targets Akt3, facilitating the ubiquitin-proteasome mediated degradation of this protein. This compound demonstrates low antiproliferative activity across 36 different cell lines. PROTAC Akt3 Degrader-1 is applicable in research focused on Triple-negative breast cancer and melanoma, aiding in the understanding of Akt3’s role in these malignancies. -
AKT Inhibitor
AKT-IN-10 is a selective inhibitor of AKT (Protein Kinase B), a crucial component of the PI3K/AKT/mTOR signaling pathway that regulates cell growth, survival, differentiation, and metabolism. This compound demonstrates significant potential for applications in cancer research, particularly in breast and prostate cancer studies, by effectively modulating AKT activity. Its ability to interfere with AKT signaling positions AKT-IN-10 as a valuable tool for investigating therapeutic strategies targeting these malignancies. -
PI3K-AKT Inhibitor
Alborixin is a potent inhibitor of the PI3K-AKT signaling pathway that promotes autophagy. It facilitates the clearance of intracellular and extracellular amyloid-β by upregulating key autophagy-related proteins such as BECN1, ATG5, and ATG7, while enhancing lysosomal activity. This mechanism yields a reduction in amyloid-β-mediated neurotoxicity, positioning Alborixin as a valuable tool for research related to Alzheimer's disease and other neurodegenerative conditions. -
APN/AKT Inhibitor
APN/AKT-IN-1 is a potent dual inhibitor targeting aminopeptidase N (APN) and protein kinase B (AKT), exhibiting IC50 values of 0.21 μM and 0.27 μM, respectively. This compound effectively blocks the phosphorylation of glycogen synthase kinase 3 beta (GSK3β), a critical substrate of AKT, thereby modulating key signaling pathways involved in cell growth, survival, and metabolism. APN/AKT-IN-1 is valuable for research applications focusing on cancer biology and therapeutic interventions targeting the APN/AKT pathway. -
Akt Inhibitor
TCL1(10-24) is a specific Akt inhibitor that targets the PH domain of Akt, disrupting its interaction with phosphoinositides. This inhibition prevents Akt's membrane translocation and subsequent activation, thereby hindering cellular proliferation and promoting apoptosis. TCL1(10-24) demonstrates significant antitumor activity in vivo, making it a valuable reagent for cancer research and studies focused on cell survival mechanisms. -
AKT1 Inhibitor
Akt1-IN-3 is a selective inhibitor of AKT1, demonstrating potent inhibition with an IC50 value of less than 15 nM against the AKT1-E17K mutant. This compound is valuable for research applications exploring the role of AKT signaling in various cancers and other diseases. Its potency and specificity make it an essential tool for studies aimed at understanding AKT1-related pathways and developing targeted therapies. -
Akt Activator
IPL344 is an Akt activator that enhances cell survival by protecting against pro-apoptotic stimuli. This compound activates the Akt signaling pathway, making it a valuable tool for studying mechanisms of neuroprotection. IPL344 is particularly relevant in the research of amyotrophic lateral sclerosis (ALS) and other conditions where Akt signaling plays a critical role. -
PI3K/BRD4 Inhibitor
PI3Kα-IN-28 is a potent dual-target inhibitor of PI3K and BRD4. This compound effectively suppresses cell proliferation in various cancer cell lines, including KYSE180 and KYSE450, while also inhibiting migration and colony formation. Additionally, PI3Kα-IN-28 induces G0/G1 phase cell cycle arrest and promotes cellular senescence by enhancing the proportion of senescent cells. Mechanistically, it decreases the levels of p-AKT and c-Myc, while activating the AMPK-p27 pathway, making it a valuable tool for cancer research, particularly in esophageal cancer studies. -
Akt Phosphorylation Inhibitor
Antiangiogenic agent 4 is an Akt phosphorylation inhibitor that effectively disrupts the Akt signaling pathway in human foreskin fibroblast (HFF) and human umbilical vein endothelial cells (HUVEC). This compound demonstrates notable antiangiogenic activity, making it a valuable tool in cancer research aimed at understanding tumor growth and vascularization mechanisms. -
PI3K/AKT Inhibitor
PI3K/AKT-IN-2 is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) and AKT signaling pathways. This compound effectively prevents epithelial-mesenchymal transition (EMT) and promotes apoptosis in various cancer cell lines. Additionally, PI3K/AKT-IN-2 has been shown to inhibit tubulin polymerization, making it a valuable tool for research into cancer metastasis and cell proliferation. -
AKT PROTAC Degrader
MS15 is a selective AKT PROTAC degrader that demonstrates potent inhibition of AKT isoforms 1, 2, and 3, with IC50 values of 798 nM, 90 nM, and 544 nM, respectively. This compound facilitates the targeted degradation of AKT, making it a valuable tool for investigating AKT-related signaling pathways. Its applications include studying cellular processes like metabolism, growth, and survival in various cancer models. -
PDK1/Akt/Flt Pathway Inhibitor
PDK1/Akt/Flt dual pathway inhibitor selectively targets the PDK1/Akt/Flt signaling pathways, crucial for cell survival and proliferation. This compound demonstrates significant inhibitory activity, making it a valuable tool for research in cancer biology and therapeutic development. It can be utilized to explore the roles of these pathways in oncogenesis and to assess potential therapeutic strategies against malignancies driven by aberrant PDK1/Akt/Flt signaling. -
Akt/PKA Inhibitor
Akt1&PKA-IN-1 is a potent dual inhibitor targeting both Akt and Protein Kinase A (PKA), exhibiting IC50 values of 0.03 μM for PKAα and 0.11 μM for Akt, with a higher IC50 of 9.8 μM for cyclin-dependent kinase 2 (CDK2). This compound demonstrates selective inhibition of CDK2, making it a valuable tool for research in cancer biology and cellular signaling pathways. Akt1&PKA-IN-1 is useful for studying the regulatory role of these kinases in cellular processes and potential therapeutic applications. -
PI3Kγ Inhibitor
TASP0415914 is a potent and orally active inhibitor of PI3Kγ, exhibiting an IC50 of 29 nM. In addition, it demonstrates significant inhibitory activity against Akt with an IC50 of 294 nM. This compound is applicable in research focused on inflammatory diseases and may provide insights into the modulation of signaling pathways involved in inflammation. -
PIM/PI3K/AKT/mTOR Inhibitor
IBL-302 is an orally available dual inhibitor targeting PIM and the PI3K/AKT/mTOR pathways. It exhibits significant antitumor activity against breast cancer and neuroblastoma, showing in vivo efficacy in nude mouse xenograft models by overcoming trastuzumab resistance. Additionally, IBL-302 enhances the cytotoxic effects of commonly used chemotherapeutic agents, including cisplatin, doxorubicin, and etoposide, making it a valuable compound for cancer research applications. -
Akt/mTOR Inhibitor
MKC-1 is an orally active and potent inhibitor targeting the Akt/mTOR signaling pathway. This compound exhibits broad antitumor activity by arresting cellular mitosis and inducing apoptosis. MKC-1 interacts with various cellular proteins, including tubulin and members of the importin β family, making it valuable for research in cancer cell cycle regulation and therapeutic mechanisms. -
Akt3 Degrader
Akt3 degrader 1 is a selective degrader that targets Akt3, effectively overcoming Osimertinib-induced resistance in H1975OR non-small cell lung cancer (NSCLC) cells. This compound demonstrates anti-proliferative effects and significantly inhibits tumor growth in murine models. Akt3 degrader 1 is a valuable tool for investigating mechanisms of drug resistance in NSCLC and can facilitate the development of novel therapeutic strategies. -
Akt1 Inhibitor
24-Methylenecycloartanyl ferulate is identified as a potential ATP-competitive inhibitor of Akt1, with an EC50 value of 33.3 μM. This compound has been shown to promote the expression of parvin-beta in human breast cancer cells, suggesting its role in modulating important signaling pathways. As a research tool, it may be valuable for studying Akt1-related biological processes and their implications in cancer research. -
Src/Akt Inhibitor
Chrysotoxine is a dual inhibitor of the Src and Akt signaling pathways. It effectively suppresses cancer stem cell phenotypes by down-regulating the Src/Akt pathway, leading to reduced cell viability and increased apoptosis in H460 and H23 cancer cell lines, while sparing non-tumor cell lines. Due to its rapid excretion and low bioavailability in animal studies, Chrysotoxine serves as a valuable tool in cancer research, particularly for investigating therapies targeting cancer stem cells. -
AKT/mTOR Inhibitor
Dehydrovomifoliol is a dual inhibitor of the AKT/mTOR signaling pathway. It effectively reduces lipid accumulation and lipogenesis, making it a valuable reagent in the study of nonalcoholic fatty liver disease (NAFLD). The compound's targeted inhibition of AKT and mTOR provides insights into metabolic regulation and potential therapeutic strategies for liver-related disorders. -
PI3K/Akt/mTOR signaling pathway Inhibitor, TLR4 signaling Inhibitor
25(R,S)-Ruscogenin is a potent inhibitor of the PI3K/Akt/mTOR and TLR4 signaling pathways. This compound effectively suppresses hepatocellular carcinoma (HCC) metastasis by decreasing the expression of matrix metalloproteinases (MMP-2 and MMP-9), uPA, VEGF, and HIF-1α. Additionally, 25(R,S)-Ruscogenin mitigates LPS-induced apoptosis in pulmonary endothelial cells, highlighting its potential for applications in cancer research and inflammatory disease studies. -
p70S6K/Akt Inhibitor
M2698 is a selective inhibitor targeting p70S6K and Akt, functioning through an ATP-competitive mechanism. With IC50 values of 1 nM for both p70S6K and Akt1/Akt3, M2698 demonstrates potent inhibitory effects on these kinases. This compound is capable of crossing the blood-brain barrier, making it a valuable tool for research in cancer biology and potential therapeutic applications in neurologic conditions. -
Akt Inhibitor
AKT Kinase Inhibitor hydrochloride is a selective inhibitor of AKT kinase, primarily known for its anti-tumor properties. This compound demonstrates significant potential in cancer research by disrupting the AKT signaling pathway, which is often activated in various malignancies. Additionally, it features an alkyne functional group, facilitating its use in click chemistry applications, particularly in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing molecules. -
Akt Inhibitor
AKT-IN-6 is a potent inhibitor of the AKT family of serine/threonine kinases, specifically targeting Akt1, Akt2, and Akt3 with IC50 values of less than 500 nM. This compound is widely utilized in biochemical research to elucidate the role of AKT signaling in various cellular processes, including cell growth, metabolism, and apoptosis. AKT-IN-6 serves as a valuable tool for investigating therapeutic approaches in cancer, diabetes, and neurodegenerative diseases where AKT activity is dysregulated. -
Akt Inhibitor
FPA-124 is a selective Akt inhibitor that operates by targeting both the pleckstrin homology (PH) and kinase domains of Akt. With an IC50 of 0.1 μM, FPA-124 demonstrates significant biological activity in promoting apoptosis. This compound is primarily utilized in research applications focused on cancer biology and signaling pathways associated with the Akt protein. -
Akt1 Inhibitor
A-674563 hydrochloride is a selective inhibitor of Akt1, exhibiting a Ki value of 11 nM. This compound effectively disrupts Akt1 signaling, making it a valuable tool for investigating the role of this kinase in cellular processes such as metabolism, survival, and proliferation. A-674563 hydrochloride is suitable for use in various research applications, including cancer research and studies focused on metabolic disorders. -
PI3K-Akt Inhibitor
(E)-Akt inhibitor-IV is a potent PI3K-Akt inhibitor that selectively targets the Akt signaling pathway. It demonstrates significant cytotoxic activity against various cancer cell lines, making it a valuable tool for studying tumor biology and therapeutic resistance. Research applications include investigating the role of Akt in cell proliferation, survival, and apoptosis in cancer models. -
Akt Activator
Tilorone is an Akt activator known for its role as an orally active antiviral agent and interferon inducer. It stimulates interferon production primarily in lymphoid tissues, exerting significant antiviral effects while also showing potential as a chemotherapeutic agent. Additionally, Tilorone enhances glucose uptake in vivo and in skeletal muscle cells by modulating Akt2/AS160 signaling and increasing glucose transporter levels, suggesting its applicability in research related to type 2 diabetes and metabolic modulation. -
AKT1 Inhibitor
Tanerasertib is an inhibitor of AKT1, specifically targeting the AKT1E17K mutant with an EC50 range of 15-60 nM. This compound exhibits significant biological activity that may be leveraged in cancer research, particularly in studies focusing on the role of the AKT signaling pathway in tumorigenesis and treatment resistance. Its application in preclinical models can provide insights into therapeutic strategies for cancers harboring AKT1 mutations. -
Akt Inhibitor
K-80003 is a potent Akt inhibitor that specifically targets and inhibits tRXRα-dependent Akt activation. This compound exhibits significant biological activity in suppressing cancer cell growth, making it valuable in cancer research. K-80003 is useful for studies investigating Akt signaling pathways and therapeutic strategies against malignancies. -
Akt Inhibitor
1-Formyl-beta-carboline is an alkaloid that functions as an Akt inhibitor, disrupting key signaling pathways. It demonstrates significant inhibitory activity against Newcastle disease virus (NDV), with IC50 values below 10 μM and over 90% inhibition at 20 μM concentration. The compound primarily targets the adsorption and entry phases of the NDV life cycle by directly interacting with the NDV hemagglutinin-neuraminidase (HN) protein. Additionally, 1-Formyl-beta-carboline affects viral entry through modulation of the PI3K/Akt signaling pathway. -
Akt Inhibitor
Hu7691 is a selective Akt inhibitor that exhibits potent inhibitory activity with IC50 values of 4.0 nM, 97.5 nM, and 28 nM against Akt1, Akt2, and Akt3, respectively. This compound has been shown to inhibit tumor growth while reducing cutaneous toxicity in mouse models, making it a valuable tool for cancer research. Its specificity and efficacy position Hu7691 as a promising reagent for studies focused on the Akt signaling pathway and its role in tumorigenesis. -
pan-AKT Inhibitor
Vevorisertib is a potent and selective pan-AKT serine/threonine kinase inhibitor, effectively targeting AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). This orally active compound demonstrates significant biological activity in inhibiting AKT pathways and is applicable in the study of solid tumors harboring PIK3CA, AKT, or PTEN mutations. Vevorisertib can be utilized as a monotherapy or in combination with other anti-cancer agents for enhanced therapeutic efficacy in cancer research. -
PI3K Inhibitor
HL-8 is a potent PI3Kα degrader that functions through the targeted protein degradation mechanism of PROTAC technology. By promoting the ubiquitination and subsequent degradation of PI3Kα, HL-8 effectively reduces phospho-AKT levels, thereby interfering with key signaling pathways associated with cancer progression. This compound exhibits significant anticancer activity against colon and cervical cancer, making it a valuable tool for research in cancer biology and therapeutic development.
